^
Association details:
| Biomarker: | EGFR exon 19 deletion + TP53 mutation + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-050 - A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
Published date:
07/12/2022
Excerpt:
We included 5 patients with EGFRm NSCLC and LM at Nanjing Chest Hospital, whose median age was 54 years, predominantly female (80%). EGFR mutations included exon 21 L858R mutation, T790M mutation, exon 19 deletion combined with TP53 mutation, and c-MET amplification....Aumolertinib in combination with bevacizumab has shown significant efficacy in patients with LM NSCLC with exon 19 deletion and exon 21 L858R mutations, even in combination with non-sensitive mutations and poor physical status.
